Group items tagged

The purpose of this Funding Opportunity Announcement (FOA) is to facilitate the design, conduct, and completion of clinical trials for improving prevention of human papillomavirus (HPV)-related cancers in human immunodeficiency virus (HIV)-infected individuals. To serve this goal, the FOA will support a network of international collaborative sites conducting meritorious and appropriately designed prevention clinical trials in the Latin American and Caribbean (LAC) region via a U54 Partnership Centers mechanism. Each proposed U54 Partnership Center must be based on a collaboration between a research institution in the United States (as the applicant institution) and partnering institution(s) in low- and middle-income countries (LMICs) in the LAC region. The proposed clinical trials should be focused on optimizing clinical prevention interventions among HIV-infected individuals, including immunoprevention (vaccination), screening and triage, and precancer treatment. Each Partnership Center application must propose a Clinical Trials Program that will develop and conduct three prevention clinical trials within the 5-year project period. As infrastructure supporting the Clinical Trials Program, each Partnership Center should include an Administrative and Coordinating Core, a Data Management and Statistical Core, and a Central Laboratory Core. Results of the clinical trials conducted through the Partnership Centers are expected to influence the development of clinical practice guidelines to improve preventive clinical care and reduce the burden of highly preventable HPV-related cancers in HIV-infected individuals.

The Landon Foundation-AACR INNOVATOR Award for Cancer Prevention Research was established to recognize the outstanding achievement of a junior faculty-level scientist working in the field of cancer prevention, and support his or her novel and innovative research that, if successful, will have the potential for high impact in the cancer prevention field. The goal of the grant program is to encourage junior faculty who are in the first five years of a faculty appointment (at the start of the grant term) to pursue novel, high-risk, high-reward cancer prevention research. Travel support is included to help foster interactions and collaborations among cancer scientists studying various aspects of cancer biology and to disseminate scientific knowledge about cancer prevention research within the field.

Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) proposes and will support the Cancer Prevention Clinical Trials Network (CP-CTNet), for which the goals are as follows: Design and conduct of early phase clinical trials to assess the safety, tolerability, and cancer preventive potential of agents and interventions of varying classes, many of which target molecules or processes known to be important during carcinogenesis. These trials include phase 0 (micro-dosing), phase I (dose-finding), and phase II (preliminary efficacy) clinical trials. Characterization of the effects of these agents and interventions on their molecular targets, as well as on other biological events associated with cancer development (such as cell proliferation, apoptosis, growth factor expression, oncogene expression, immune response) and correlation of these effects with clinical endpoints. Development of further scientific insights into the mechanisms of cancer prevention by the agents examined, including the development of novel potential markers as determinants of response.

This Funding Opportunity Announcement (FOA) is a part of the National Cancer Institute (NCI) initiative intended to support Cancer Prevention Clinical Trials Network (CP-CTNet). The goals for the CP-CTNet include: Design and conduct early phase clinical trials to assess the safety, tolerability, and cancer preventive potential of agents and interventions of varying classes, many of which target molecules or processes known to be important during carcinogenesis. These trials include phase 0 (microdosing), phase I (dose-finding), and phase II (preliminary efficacy) clinical trials; Characterization of the effects of these agents and interventions on their molecular targets, as well as on other biological events associated with cancer development (such as cell proliferation, apoptosis, growth factor expression, oncogene expression, immune response) and correlation of these effects with clinical endpoints. Development of further scientific insights into the mechanisms of cancer prevention by the agents examined, including the development of novel potential markers as determinants of response.

This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) proposing commercially-directed research for the development of cancer prevention, diagnosis, or treatment technologies to improve cancer outcomes in low- and middle-income countries (LMICs), and low-resource settings in the US. Specifically, the FOA solicits encourages grant applications from SBCs to develop or adapt, apply, and validate existing or emerging technologies into user-friendly products for cancer prevention, diagnosis, or treatment in low-resource settings. These technologies should be practical and affordable in the low-resource settings, including remote or underserved populations within or outside the US. The technologies may include, but are not limited to tools for vaccine dissemination/delivery, imaging, in vitro diagnosis, or treatment of pre-cancerous (pre-neoplastic) or cancerous lesions that are preventable or treatable within low-resource settings. Strong emphasis is placed on technologies that directly provide or immediately lead to treatment options available in the local health system.

Tobacco use remains the leading preventable cause of disease and death in the United States. More than half of smokers attempt to quit each year, but fewer than one in ten succeed. Evidence-based cessation treatments, including individual, group, and telephone counseling and seven FDA-approved cessation medications, exist, but are underutilized. The Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health is announcing the opportunity to apply for funds for a competitive, non-research cooperative agreement to provide technical assistance to state tobacco control programs and other partners to translate the science of tobacco control cessation into public health action in order to further increase the rate of cessation among tobacco users in the United States. The funded organizations will accomplish this by providing technical assistance to state tobacco control programs and other partners to 1) Implement health systems change initiatives that seek to integrate tobacco dependence treatment into routine clinical care, including care of persons with behavioral health conditions; and 2) Improve state quitlines' infrastructure, operations, and services to further enhance their effectiveness and efficiency, increase state quitlines' reach, especially among populations experiencing tobacco-related disparities, broaden the range of cessation services offered by state quitlines, and enhance quitline sustainability.

This Funding Opportunity Announcement (FOA) invites applications that seek to apply one or more innovative methodologies in communication research across the cancer control continuum, from prevention, early detection, diagnosis, treatment, and survivorship, to end of life. Applications to this FOA should utilize one or more of the following analytic approaches, methods, and data sources, including but not limited to social media data mining, Natural Language Processing (NLP) techniques, online social network analysis, crowdsourcing research tools (e.g., mTurk), online search data, Ecological Momentary Assessment, neuroscience and biobehavioral approaches to communication, and geographic information systems. Studies should assess outcomes related to cancer prevention and control (e.g., knowledge, attitudes, beliefs, perceived risk, decision making in screening and treatment, information inequalities, social support, shared decision making, persuasion, caregiving, behavioral intentions, preventive behaviors, and policy support, among others). This FOA utilizes the Exploratory/Developmental Grant (R21) mechanism, which supports investigation of novel scientific ideas or new model systems, tools, or technologies that have the potential for significant impact on biomedical or biobehavioral research.

This Funding Opportunity Announcement (FOA) invites applications that seek to apply one or more innovative methodologies in communication research across the cancer control continuum, from prevention, early detection, diagnosis, treatment, and survivorship, to end of life. Applications to this FOA should utilize one or more of the following analytic approaches, methods, and data sources, including but not limited to social media data mining, Natural Language Processing (NLP) techniques, online social network analysis, crowdsourcing research tools (e.g., mTurk), online search data, Ecological Momentary Assessment, neuroscience and biobehavioral approaches to communication, and geographic information systems. Studies should assess outcomes related to cancer prevention and control (e.g., knowledge, attitudes, beliefs, perceived risk, decision making in screening and treatment, information inequalities, social support, shared decision making, persuasion, caregiving, behavioral intentions, preventive behaviors, and policy support, among others). Also listed under R21

Centers for Disease Control and Prevention (CDC) supports a variety of activities in health departments and organizations aimed at preventing and controlling cancer, the second leading cause of death in US men and women. Since the passage of the Cancer Registries Amendment Act in 1992, the National Program of Cancer Registries (NPCR) has collected data on cancer occurrence, extent, treatment and outcomes in over 45 states and jurisdictions, representing 96% of the US population. CDC's Division of Cancer Prevention and Control (DCPC) has supported successful partnerships with national organizations to define standardized practices in U.S. cancer surveillance and assure and complete, timely, and high-quality data for the official federal U.S. Cancer Statistics. The purpose of this funding opportunity is to build strong partnerships among national organizations involved directly in cancer surveillance in order to enhance the data quality and operational efficiency of CDC’s National Program of Cancer Registries (NPCR). This program has three essential components: 1) Education, Translation and Quality Control of cancer surveillance standards and best practices; 2) Cancer Staging Collaboration and Support; and 3) Standardization and Support for Laboratory and Biomarker Electronic Reporting. The overarching goal of this project is to collaboratively define and promote uniform standards in cancer staging, collection and reporting. Funded entities will identify specific enhancement needs of cancer registries and support cancer surveillance professionals, including reporters (e.g. facilities, labs), tumor registrars, and registries to submit high quality, standardized data via central cancer registries to NPCR. Relevant performance measures will be used to assess the recipients’ activities that enhance the standards, quality, and operations of NPCR cancer surveillance system.

The “Partner Actions to Improve Oral Health” program is a five-year competitive renewal to continue CDC investment in and support of oral health promotion and disease prevention programs. The purpose is to build the strength and effectiveness of state oral health programs recipients to prevent and control oral diseases and related conditions. Under component 1, recipient will work with all NOFO DP18-1810 funded programs to provide technical assistance, training, and capacity building resources for: 1) the Basic Screening Survey, 2) evidence-based oral health strategies (i.e., school sealant programs and community water fluoridation) and infection prevention and control practices, 3) oral health surveillance, 4) evaluation of oral health programs, and 5) reports on the oral health program capacity for all 50 states (CDC-funded and non-funded states). Under component 2, recipient will work with six programs selected NOFO DP18-1810 to integrate oral health with other chronic disease programs (i.e., medical/dental integration). Recipient will provide technical assistance for medical/dental integration programs, and compile examples of effective medical/dental integration programs and strategies. The proposed program will replace and build upon FOA 13-1313 [FY2013-FY2018]. Successful implementation and execution of the NOFO strategies will result in decreases in dental caries, oral health disparities, and co-morbid chronic diseases.

This Funding Opportunity Announcement (FOA) invites applications for P30 Cancer Center Support Grants (CCSGs) to support NCI-designated Cancer Centers. CCSGs support two types of cancer centers: 1) Comprehensive Cancer Centers, which demonstrate reasonable depth and breadth of research activities in each of three major areas: basic laboratory; clinical; and prevention, control and population-based research, and which have substantial transdisciplinary research that bridges these scientific areas; and 2) Cancer Centers, which are primarily focused on basic laboratory; clinical; and prevention, cancer control, and population-based research; or some combination of these areas. The purpose of both types of NCI-designated Cancer Centers is to capitalize on all institutional cancer research capabilities, integrating meritorious programs in laboratory, clinical, and population research into a single transdisciplinary research enterprise across all institutional boundaries. Cancer Centers supported through this FOA are expected to serve as major sources of discovery of the nature of cancer and of development of more effective approaches to prevention, diagnosis, and therapy; to contribute significantly to the development of shared resources that support research; to collaborate and coordinate their research efforts with other NCI-funded programs and investigators; and to disseminate research findings for the benefit of the community.

This Funding Opportunity Announcement (FOA) invites applications for P30 Cancer Center Support Grants (CCSGs) to support NCI-designated Cancer Centers. CCSGs support three types of Cancer Centers: 1) Comprehensive Cancer Centers, which demonstrate reasonable depth and breadth of research activities in each of three major areas: basic laboratory; clinical; and prevention, control and population-based research, and which have substantial transdisciplinary research that bridges these scientific areas; and 2) Clinical Cancer Centers, which are primarily focused on basic laboratory; clinical; and prevention, cancer control, and population-based research; or some combination of these areas, and 3) Basic Cancer Centers, which focus on basic laboratory research. The purpose of all types of NCI-designated Cancer Centers is to capitalize on all institutional cancer research capabilities, integrating meritorious research into a single transdisciplinary research enterprise across all institutional boundaries. Cancer Centers supported through this FOA are expected to serve as major sources of discovery of the nature of cancer and of development of more effective approaches to prevention, diagnosis, and therapy; to contribute significantly to the development of Shared Resources that support research; to collaborate and coordinate their research efforts with other NCI-funded programs and investigators; and to disseminate research findings for the benefit of the community.

The National Cancer Institute (NCI), through its Center for Global Health (CGH), seeks to promote cancer prevention and control (CPC) research in low- and middle-income countries (LMICs) through collaborations and research partnerships between the NCI-designated cancer centers and partner institutions in LMICs. Through this funding opportunity announcement (FOA), the NCI will provide administrative supplement awards to currently-funded P30 NCI-designated cancer center grantees to support pilot research plans that focus on cancer prevention and control. These supplements are designed to stimulate and strengthen CPC twinning programs between researchers at the NCI-designated cancer centers and institutions in LMICs. It is anticipated that outcomes of this supplement will include collaborative research grants between investigators at the NCI-designated cancer centers and LMIC institutions.

The purpose of this Funding Opportunity Announcement (FOA) is to facilitate the design, conduct, and completion of clinical trials for improving prevention of human papillomavirus (HPV)-related cancers in human immunodeficiency virus (HIV)-infected individuals. To serve this goal, the FOA will support a network of international collaborative sites conducting meritorious and appropriately designed prevention clinical trials in the Latin American and Caribbean (LAC) region via a U54 Partnership Centers mechanism.

Cigarette smoking and exposure to secondhand smoke (SHS) is the leading preventable cause of death in the United States, resulting in approximately 480,000 premature deaths and 16 million smoking-related illnesses. Cigarette smoking can lead to increased cardiovascular disease, multiple types of cancer, pulmonary disease, adverse reproductive outcomes, and the exacerbation of chronic health conditions. Annual costs associated with tobacco-related illnesses amount to nearly $280 billion in medical expenses and lost productivity. Electronic cigarette (e-cigarette) use among U.S. youth and young adults has increased considerably, growing 900% among high school students from 2011 to 2015. Cancer is the second leading cause of death in the United States, with approximately 1.5 million new diagnoses and over 550,000 deaths each year. Commercial Tobacco use is the leading preventable cause of cancer and cancer deaths. It can cause not only lung cancer but also cancers of the mouth and throat, voice box, esophagus, stomach, kidney, pancreas, liver, bladder, cervix, colon and rectum, and a type of leukemia.

The purpose of the program is to identify international cancer control practices that can be applied to our domestic programs. Program activities will focus on 1) the establishment or strengthening of high quality cancer registries through establishment of centers for excellence in U.S. territories and other CDC global focus regions, 2) technical exchanges between CDC and the awardee, 3) consultations from global experts to help inform CDC's priority cancer activities, and 4) collaboration on the development and dissemination of monographs and other publications that promote evidence-based prevention for cervical (and other HPV-related), breast, lung, skin, colorectal and other types of cancer. Together, these activities represent an important opportunity for CDC to strengthen its programs in cancer prevention and control.

The purpose of this funding opportunity is to establish a program of research to advance the understanding, prevention and treatment of pediatric multiple organ dysfunction syndrome (MODS). Given the prevalence and associated morbidity and mortality of MODS in children, the current lack of understanding underscores the need for more exploratory research. Possible topics of study include, but are not limited to, the epidemiology, pathophysiology, monitoring, and treatment of MODS. Studies that assess specific etiologies associated with MODS including, but not limited to, sepsis, trauma, acute respiratory distress syndrome, inborn errors of metabolism, burns, cancer, transplantation and congenital heart disease are encouraged. Applications may include any appropriate study design ranging from basic science animal models through small prospective randomized controlled trials. The intent of this R21 funding initiative is to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of research projects addressing these topics. These studies may incur considerable research risk in efforts to make important breakthroughs in the understanding, prevention and treatment of MODS in children. Projects of limited cost or scope that use widely accepted approaches and methods within well-established fields are better suited for the R03 small grant activity code. It is hoped that the results of this exploratory research will translate into improved clinical outcomes for children with, and at risk for MODS.

Through its Epidemiology Grants program, the foundation awards two-year grants of up to $200,000 to support investigators pursuing epidemiological research aimed at improving our understanding of childhood cancer. The program is designed to support hypothesis-driven research that focuses on the epidemiology, early detection, and prevention of childhood cancer or comparative effectiveness and outcomes research related to detection, prevention, and treatment.

Alex's Lemonade Stand Foundation Epidemiology Grants are $100,000 per year for two years. Funding is expected to allow investigators to pursue epidemiological approaches to significantly add to the understanding of childhood cancers. These awards are expected to provide funds that will support investigators pursuing epidemiological research aimed at improving our understanding of childhood cancer. This grant mechanism is designed to support hypothesis-driven research that focuses on the epidemiology, early detection and prevention of childhood cancer or comparative effectiveness and outcomes research related to detection, prevention and treatment.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage projects to generate fundamental knowledge of affective processes. Basic affective science projects should have key downstream consequences for single (e.g., genetic testing consent) and multiple (e.g., adherence to oral chemotherapy regimen) event decisions and behaviors across the cancer prevention and control continuum. The FOA is expected to encourage scientific disciplines that have not traditionally conducted cancer research such as affective and cognitive neuroscience, decision science, and consumer science to elucidate perplexing and understudied problems in basic affective and decision sciences with promise of having downstream implications for cancer prevention and control science.